



**meetings  
in a box**

ROAD TO



**ASCO 2025**

A cura di Marco Tagliamento, Genova



ACCADEMIA NAZIONALE DI MEDICINA

# BREAST CANCER

ROAD TO... ASCO 2025

Chicago, 30<sup>th</sup> May - 3<sup>rd</sup> June 2025



## METASTATICO

### SERENA-6

Camizestrant + CDK4/6 inhibitor for the treatment emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer (**LBA4 - Plenary Session**)

### ASCENT-04/KEYNOTE-D19

Sacituzumab govitecan + pembrolizumab vs chemotherapy + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (**LBA109**)

### DESTINY-Breast 09

Trastuzumab deruxtecan + pertuzumab vs taxane + trastuzumab + pertuzumab for first-line treatment of patients with HER2-positive advanced/metastatic breast cancer (**LBA1008**)

## LOCALIZZATO

### neoCARHP

De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (**LBA500**)

# LUNG CANCER

ROAD TO... ASCO 2025

Chicago, 30<sup>th</sup> May - 3<sup>rd</sup> June 2025



## NSCLC METASTATICO

### HERTHENA-Lung02

Patritumab deruxtecan in resistant EGFR-mutated advanced NSCLC after a third-generation EGFR TKI (Abs 8005)

### KRYSTAL-7

First-line adagrasib with pembrolizumab in patients with advanced/metastatic KRASG12C-mutated NSCLC (Abs 8506)

## NSCLC LOCALIZZATO/LOCALMENTE AVANZATO

### NeoADAURA

Neoadjuvant osimertinib ± chemotherapy vs chemotherapy alone in resectable EGFR-mutated NSCLC (Abs 8001)

### CheckMate 816

Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC (LBA8000)

## SCLC

### DeLLphi-304

Tarlatamab versus chemotherapy as second-line treatment for SCLC (LBA8008)

# GASTROINTESTINAL CANCER

**ROAD TO... ASCO 2025**

Chicago, 30<sup>th</sup> May - 3<sup>rd</sup> June 2025



## **Alliance A021502; ATOMIC**

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III dMMR colon cancer

**(LBA01 - Plenary Session)**

## **MATTERHORN**

Durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer **(LBA5 - Plenary Session)**

# GYNECOLOGICAL CANCER

ROAD TO... ASCO 2025

Chicago, 30<sup>th</sup> May - 3<sup>rd</sup> June 2025



## FIRST/ENGOT-OV44

Dostarlimab and niraparib in first-line advanced ovarian cancer (**LBA556**)

# GENITOURINARY CANCER

## JAVELIN Bladder Medley

Avelumab + sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma (**Abs 4501**)

## ANZUP 1301

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer (**LBA4504**)

# MELANOMA

ROAD TO... ASCO 2025

Chicago, 30<sup>th</sup> May - 3<sup>rd</sup> June 2025



## RELATIVITY-098

Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma (**LBA9055**)

# HEAD&NECK

## NIVOPOSTOP (GORTEC 2018-01)

Adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse (**LBA2 - Plenary Session**)